Lamivudine News
Low-Dose Tenofovir Shows Efficacy in Patients With Lamivudine-Resistant Hepatitis B Virus: Presented at IM
Virologic breakthrough during hepatitis B virus (HBV) treatment with lamivudine is associated with the occurrence of YMDD mutations. Tenofovir disoproxil fumarate (TDF), an inhibitor of viral DNA polymerase approved for HIV...
HIV/AIDS Update - Epivir Tablets for Pediatric Dosing
FDA has approved a new formulation of Epivir (lamivudine) designed to facilitate dosing in appropriate pediatric patients who can reliably swallow tablets. Epivir is now available as 150 mg scored tablets. The scored tablets...
Abacavir/Lamivudine Noninferior to Tenofovir/Emtricitabine as Backbone to Lopinavir/Ritonavir HIV Therapy: Presented at CROI
Doctors reported that the combination of the nucleoside reverse transcriptase inhibitors abacavir/lamivudine appears to be noninferior to the nucleotide/nucleoside reverse transcriptase inhibitor combination of...
What is the more suitable for early detection of low abundant lamivudine-resistant mutants?
Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and advanced liver diseases. However, long-term lamivudine monotherapy leads to the emergence of lamivudine-resistant hepatitis B virus...
WHO Adds Three Ranbaxy Antiretrovirals to Prequalification List
Indian pharmaceutical company Ranbaxy Laboratories on Monday announced that the World Health Organization has added three of its antiretroviral drugs to WHO's list of prequalified antiretrovirals, Reuters India reports